Every week, a curated summary of FDA actions, compounding rulings, new research, and regulatory changes for BPC-157, GLP-1, GHK-Cu, TB-500, and Ipamorelin. Research-first. No vendor relationships. Unsubscribe anytime.
Enter your email — we'll send a confirmation, then the first issue. No checkout. No countdown timers.
Each issue pulls from the same primary-source log that powers the Regulatory Updates page — no vendor press releases, no aggregator summaries.
FDA warning letters, import alerts, compounding eligibility changes, and WADA prohibited-list additions since the last issue.
Preprints and published studies added to the catalog peptides — with a one-line summary of what the design was and what it actually showed.
Tier upgrades or downgrades when meaningful new data land — the same evidence-tier system used in the deep-dive pages.
Same editorial standards as the free research pages. No vendor relationships, no affiliate links. When evidence is weak, we say so. When regulatory status is ambiguous, we link to the primary source rather than paraphrase it.
The Regulatory Updates Log is the running source the digest pulls from.